Baricitinib is the first-generation JAK 1/2 inhibitor blocking cytokine signaling, including IL-4, IL-5, and IL-13, registered for the treatment of moderate-to-severe AD in the United States and Europe. Here, IL4 is linked to Alzheimer disease.